Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

Abstract This study presents a Delphi consensus developed by the Headache Study Group of the Spanish Society of Neurology (GECSEN) to establish updated recommendations on key aspects of preventive migraine management. Given the high global burden of migraine and the emergence of novel preventive therapies—particularly OnabotulinumtoxinA and Calcitonin gene-related peptide (CGRP)-targeted treatments—there is a need to redefine therapeutic goals and optimize clinical decision-making. A nine-member Steering Committee defined 14 statements addressing five domains: candidate patient selection, therapeutic goals, treatment discontinuation, switching strategies, and combination therapy. A systematized literature review (171 selected publications) informed statement development. Eighty-eight migraine specialists participated in the first Delphi round and 48 in the second. Consensus was determined using the RAND/UCLA appropriateness method. Agreement was achieved for all 14 recommendations after two voting rounds. Preventive therapy is recommended in patients with ≥ 4 monthly migraine or moderate-to-severe headache days and relevant quality-of-life impairment. The ideal therapeutic goal is migraine freedom or minimization of attack frequency and intensity with improved quality of life. Optimal control is defined as < 4 monthly moderateto-severe headache days within three months. Treatment should generally be maintained for at least 12 months after achieving optimal control. Switching or combining preventive therapies—including CGRP monoclonal antibodies, gepants, and OnabotulinumtoxinA—may be considered in insufficient responders. This consensus proposes a treat-to-target strategy centered on patient-reported outcomes and residual disease burden, aiming to standardize preventive migraine care and improve long-term clinical outcomes.

Authors

Publication Details

Journal
Neurological Sciences
Published
2026-11-16
DOI
https://doi.org/10.1007/s10072-026-09538-8
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

Isabel Colomina, Sonia Santos Lasaosa, Jesús Porta-Etessam, Pablo Irimia et al.
Neurological Sciences
Migraine and Headache Studies
article

Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

Isabel Colomina, Sonia Santos Lasaosa, Jesús Porta-Etessam, Pablo Irimia, Ángel Luis Guerrero Peral, Julio Pascual, Patricia Pozo‐Rosich, Carmen González Oria, S. Díaz-Insa, R. Belvís
article en

Abstract

Abstract This study presents a Delphi consensus developed by the Headache Study Group of the Spanish Society of Neurology (GECSEN) to establish updated recommendations on key aspects of preventive migraine management. Given the high global burden of migraine and the emergence of novel preventive therapies—particularly OnabotulinumtoxinA and Calcitonin gene-related peptide (CGRP)-targeted treatments—there is a need to redefine therapeutic goals and optimize clinical decision-making. A nine-member Steering Committee defined 14 statements addressing five domains: candidate patient selection, therapeutic goals, treatment discontinuation, switching strategies, and combination therapy. A systematized literature review (171 selected publications) informed statement development. Eighty-eight migraine specialists participated in the first Delphi round and 48 in the second. Consensus was determined using the RAND/UCLA appropriateness method. Agreement was achieved for all 14 recommendations after two voting rounds. Preventive therapy is recommended in patients with ≥ 4 monthly migraine or moderate-to-severe headache days and relevant quality-of-life impairment. The ideal therapeutic goal is migraine freedom or minimization of attack frequency and intensity with improved quality of life. Optimal control is defined as < 4 monthly moderateto-severe headache days within three months. Treatment should generally be maintained for at least 12 months after achieving optimal control. Switching or combining preventive therapies—including CGRP monoclonal antibodies, gepants, and OnabotulinumtoxinA—may be considered in insufficient responders. This consensus proposes a treat-to-target strategy centered on patient-reported outcomes and residual disease burden, aiming to standardize preventive migraine care and improve long-term clinical outcomes.

Neurological SciencesVol. 47(12)
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon